Serving Australia and NZ
1300 543 373


RIG-I & Cancer Immunotherapy

Download Newsletter

Inside this issue: 

New reporter cells Signaling inhibitors: Transfection Enhancer: Review:
The development of immune checkpoint inhibitors (ICI) has revolutionized cancer immunotherapy. Unlike TLR9 & STING, RIG-I (a viral RNA sensor) is expressed in virtually all cell types including tumor cells. RIG-I is a promising target for cancer immunotherapy.
Get more info